Rsv Vacc, Pref A And Pref B/Pf
Brand name: Abrysvo
Rank #63 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$284.5M
Total Cost
872,396
Total Claims
$284.5M
Total Cost
6,599
Prescribers
$326
Cost per Claim
871,769
Beneficiaries
873,427
30-Day Fills
$43K
Avg Cost/Provider
132
Avg Claims/Provider
Share of Medicare Part D Spending
0.10%
of total Medicare Part D spending
$284.5M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $284.5M total
Top Prescribers of Rsv Vacc, Pref A And Pref B/Pf
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Cedric Davis | Family Practice | Lauderdale Lakes, FL | 54,336 | $17.7M |
| 2 | Lloyd Vanwinkle | Family Practice | Castroville, TX | 47,076 | $15.5M |
| 3 | Richard Clark | Family Practice | Marietta, OH | 40,444 | $13.2M |
| 4 | Ruth Mays | Family Practice | Highland Park, MI | 38,818 | $12.3M |
| 5 | Melissa Tonn | Preventive Medicine | Dallas, TX | 32,056 | $10.6M |
| 6 | Tejal Joseph | Family Practice | Fenton, MI | 28,924 | $9.2M |
| 7 | John Bogdasarian | Otolaryngology | Fitchburg, MA | 22,937 | $7.4M |
| 8 | Tasbirul Alam | Family Practice | Jackson Heights, NY | 22,995 | $7.4M |
| 9 | Peter Morris | Preventive Medicine | Raleigh, NC | 22,155 | $7.4M |
| 10 | Carisa Hines | Hospitalist | Atlanta, GA | 21,259 | $7.1M |
| 11 | Martin Duclos | Internal Medicine | Conway, SC | 21,245 | $7.0M |
| 12 | Shaun Gill | Hospitalist | Doylestown, PA | 16,743 | $5.4M |
| 13 | John Daniel | Internal Medicine | Richmond, VA | 14,256 | $4.8M |
| 14 | Kenneth Patric | Family Practice | East Ridge, TN | 9,665 | $3.2M |
| 15 | Matthew Mesnik | General Practice | Blaine, MN | 9,480 | $3.1M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 60 | Umeclidinium Brm/Vilanterol Tr (Anoro Ellipta) | $294.3M | 480,651 |
| 61 | Gabapentin (Gabapentin) | $291.0M | 15,142,335 |
| 62 | Cabozantinib S-Malate (Cabometyx) | $287.3M | 11,285 |
| 63 | Rsv Vacc, Pref A And Pref B/Pf (Abrysvo) | $284.5M | 872,396 |
| 64 | Bimatoprost (Lumigan) | $284.4M | 610,243 |
| 65 | Apremilast (Otezla) | $283.9M | 59,020 |
| 66 | Budesonide/Glycopyr/Formoterol (Breztri Aerosphere) | $280.9M | 340,138 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology